![]() These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. This release contains forward-looking statements that are subject to various risks and uncertainties. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).įor more information visit the Company’s website at Disclaimer Along with the core business, the Company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Through its network of 3,690 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 315,305 patients around the globe. ![]() “The acquisition will also deliver on Quest's strategy to accelerate growth and drive operational excellence through strategically aligned, accretive acquisitions."įresenius Medical Care and Quest will also collaborate on identifying patients with early-stage chronic kidney disease, based on Quest’s laboratory data analytics, who may benefit from treatment to slow progression to end-stage renal disease (ESRD).įresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3 million patients worldwide regularly undergo dialysis treatment. “By joining forces with Shiel, physicians and patients in the New York-New Jersey region will have broader access to Quest’s diagnostic insights and innovations,” said Steve Rusckowski, Quest Diagnostics Chairman, President and CEO. Ensuring a smooth transition will be a priority.” ![]() With this transaction, Shiel’s customers will have access to even more diagnostic expertise. “Based on the business’ development relative to our original expectations we’re keen to focus on areas offering superior growth and benefits for our core activities. “The sale of Shiel Medical Laboratory will optimize the growth profile of our portfolio of Care Coordination activities in the U.S.,” said Rice Powell, Chief Executive Officer of Fresenius Medical Care. Closing of the transaction is subject to regulatory approvals and anticipated in the fourth quarter of 2017. The divestment is expected to generate a modest book gain for Fresenius Medical Care. Fresenius Medical Care’s dialysis-related laboratory services business, Spectra Labs, is not affected by the divestiture. The decision to divest Shiel is aligned with Fresenius Medical Care’s goal to further optimize the Company’s Care Coordination portfolio. Shiel provides comprehensive non-dialysis laboratory services in the New York-New Jersey metropolitan area.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |